Ocular manifestations of Wegener's granulomatosis

Hazlita Mohd Isa, Susan Lightman, Charles D. Pusey, Simon Rj Taylor

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil cytoplasm antibodies. It can involve any organ system, but most commonly affects the respiratory and renal systems and the head and neck, including the eye. The ophthalmic manifestations of WG/GPA are diverse and can affect any of the ocular structures. Despite continuing research, the exact pathogenesis of WG/GPA remains elusive, but there is increasing awareness of the disease, especially as its prevalence and incidence are both on the rise. Unhelpfully, the diagnosis and management of WG/GPA remains a challenge, especially in its limited form, as blood tests, imaging and tissue biopsies are often negative or nonspecific. Nevertheless, the emergence of new treatment regimens for WG/GPA, particularly target-specific drugs such as rituximab, the anti-CD20 antibody, is bringing promise in providing patients with better and potentially safer treatment for the disease.

Original languageEnglish
Pages (from-to)541-555
Number of pages15
JournalExpert Review of Ophthalmology
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Eye Manifestations
Granulomatosis with Polyangiitis
Antibodies
Biopsy
Hematologic Tests
Respiratory System
Anti-Idiotypic Antibodies
Cytoplasm
Neutrophils
Blood
Neck
Head
Tissue
Kidney
Imaging techniques
Incidence
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Granulomata
  • Ocular
  • Rituximab
  • Vasculitis
  • Wegener's granulomatosis

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Mohd Isa, H., Lightman, S., Pusey, C. D., & Taylor, S. R. (2011). Ocular manifestations of Wegener's granulomatosis. Expert Review of Ophthalmology, 6(5), 541-555. https://doi.org/10.1586/eop.11.62

Ocular manifestations of Wegener's granulomatosis. / Mohd Isa, Hazlita; Lightman, Susan; Pusey, Charles D.; Taylor, Simon Rj.

In: Expert Review of Ophthalmology, Vol. 6, No. 5, 10.2011, p. 541-555.

Research output: Contribution to journalArticle

Mohd Isa, H, Lightman, S, Pusey, CD & Taylor, SR 2011, 'Ocular manifestations of Wegener's granulomatosis', Expert Review of Ophthalmology, vol. 6, no. 5, pp. 541-555. https://doi.org/10.1586/eop.11.62
Mohd Isa, Hazlita ; Lightman, Susan ; Pusey, Charles D. ; Taylor, Simon Rj. / Ocular manifestations of Wegener's granulomatosis. In: Expert Review of Ophthalmology. 2011 ; Vol. 6, No. 5. pp. 541-555.
@article{0aed021c93e14b7c9c44a3bcfd085710,
title = "Ocular manifestations of Wegener's granulomatosis",
abstract = "Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil cytoplasm antibodies. It can involve any organ system, but most commonly affects the respiratory and renal systems and the head and neck, including the eye. The ophthalmic manifestations of WG/GPA are diverse and can affect any of the ocular structures. Despite continuing research, the exact pathogenesis of WG/GPA remains elusive, but there is increasing awareness of the disease, especially as its prevalence and incidence are both on the rise. Unhelpfully, the diagnosis and management of WG/GPA remains a challenge, especially in its limited form, as blood tests, imaging and tissue biopsies are often negative or nonspecific. Nevertheless, the emergence of new treatment regimens for WG/GPA, particularly target-specific drugs such as rituximab, the anti-CD20 antibody, is bringing promise in providing patients with better and potentially safer treatment for the disease.",
keywords = "Granulomata, Ocular, Rituximab, Vasculitis, Wegener's granulomatosis",
author = "{Mohd Isa}, Hazlita and Susan Lightman and Pusey, {Charles D.} and Taylor, {Simon Rj}",
year = "2011",
month = "10",
doi = "10.1586/eop.11.62",
language = "English",
volume = "6",
pages = "541--555",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Ocular manifestations of Wegener's granulomatosis

AU - Mohd Isa, Hazlita

AU - Lightman, Susan

AU - Pusey, Charles D.

AU - Taylor, Simon Rj

PY - 2011/10

Y1 - 2011/10

N2 - Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil cytoplasm antibodies. It can involve any organ system, but most commonly affects the respiratory and renal systems and the head and neck, including the eye. The ophthalmic manifestations of WG/GPA are diverse and can affect any of the ocular structures. Despite continuing research, the exact pathogenesis of WG/GPA remains elusive, but there is increasing awareness of the disease, especially as its prevalence and incidence are both on the rise. Unhelpfully, the diagnosis and management of WG/GPA remains a challenge, especially in its limited form, as blood tests, imaging and tissue biopsies are often negative or nonspecific. Nevertheless, the emergence of new treatment regimens for WG/GPA, particularly target-specific drugs such as rituximab, the anti-CD20 antibody, is bringing promise in providing patients with better and potentially safer treatment for the disease.

AB - Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil cytoplasm antibodies. It can involve any organ system, but most commonly affects the respiratory and renal systems and the head and neck, including the eye. The ophthalmic manifestations of WG/GPA are diverse and can affect any of the ocular structures. Despite continuing research, the exact pathogenesis of WG/GPA remains elusive, but there is increasing awareness of the disease, especially as its prevalence and incidence are both on the rise. Unhelpfully, the diagnosis and management of WG/GPA remains a challenge, especially in its limited form, as blood tests, imaging and tissue biopsies are often negative or nonspecific. Nevertheless, the emergence of new treatment regimens for WG/GPA, particularly target-specific drugs such as rituximab, the anti-CD20 antibody, is bringing promise in providing patients with better and potentially safer treatment for the disease.

KW - Granulomata

KW - Ocular

KW - Rituximab

KW - Vasculitis

KW - Wegener's granulomatosis

UR - http://www.scopus.com/inward/record.url?scp=80053982553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053982553&partnerID=8YFLogxK

U2 - 10.1586/eop.11.62

DO - 10.1586/eop.11.62

M3 - Article

AN - SCOPUS:80053982553

VL - 6

SP - 541

EP - 555

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 5

ER -